MAP2 (Microtubule-Associated Protein 2) is a neuronal cytoskeletal protein that plays critical roles in stabilizing microtubules, maintaining dendritic architecture, and regulating synaptic function. As one of the most abundant proteins in neurons, MAP2 is essential for proper neuronal development, axonal transport, and plasticity. It serves as a key biomarker for neuronal injury and is heavily implicated in the pathogenesis of Alzheimer's disease and other neurodegenerative disorders. [1]
| Attribute | Value | [2]
|-----------|-------| [3]
| Protein Symbol | MAP2 | [4]
| Protein Name | Microtubule-Associated Protein 2 | [5]
| Aliases | MAP-2, MAP2A, MAP2B, MAP2C, MAP2D | [6]
| Chromosomal Location | 2q34-q35 | [7]
| Entrez Gene ID | 4135 | [8]
| UniProt ID | P29536 | [9]
| Isoforms | Multiple (MAP2A, MAP2B, MAP2C, MAP2D) | [10]
| Tissue Specificity | Neuron-specific |
MAP2 is a large protein with distinct structural domains:
| Domain | Position | Function |
|---|---|---|
| N-terminal projection domain | 1-1500 aa | Protein-protein interactions, binding to PSD-95 |
| Microtubule-binding domain | 1500-1800 aa | Direct microtubule interaction |
| C-terminal domain | 1800-2000+ aa | Regulatory functions |
The MAP2 gene produces multiple isoforms through alternative splicing:
| Isoform | Molecular Weight | Expression Pattern | Key Features |
|---|---|---|---|
| MAP2A | ~200 kDa | Adult brain | Highest molecular weight |
| MAP2B | ~200 kDa | Developmental | Most abundant isoform |
| MAP2C | ~70 kDa | Developing brain | Lacks projection domain |
| MAP2D | ~200 kDa | Adult brain | Similar to MAP2A/B |
MAP2 contains 3-4 repeat sequences in its microtubule-binding domain:
Repeat 1: 1766-1790 aa
Repeat 2: 1791-1815 aa
Repeat 3: 1816-1840 aa
Repeat 4 (if present): 1841-1865 aa
These repeats bind to the C-terminal tails of β-tubulin, stabilizing microtubule structure.
MAP2's primary function is stabilizing neuronal microtubules:
MAP2 is specifically enriched in dendrites (not axons):
| Property | Description |
|---|---|
| Dendritic localization | Concentrated in dendritic shafts and spines |
| Spine morphology | Regulates dendritic spine shape and stability |
| Synaptic targeting | Localizes to postsynaptic densities |
| Signal transduction | Scaffold for signaling molecules |
MAP2 plays essential roles at synapses:
MAP2 is intimately involved in AD pathogenesis:
| Change | Description | Significance |
|---|---|---|
| Reduced immunoreactivity | Decreased MAP2 staining | Neuronal loss indicator |
| Dendritic degeneration | Beading, fragmentation | Early pathological change |
| Colocalization with plaques | MAP2 around amyloid | Localized toxicity |
| Correlation with cognition | MAP2 loss tracks dementia | Clinical biomarker |
| Disease | MAP2 Relationship |
|---|---|
| Huntington's disease | Reduced MAP2 in striatal neurons |
| Frontotemporal dementia | Tau pathology affects MAP2 |
| Multiple sclerosis | Marker of demyelination damage |
| Traumatic brain injury | MAP2 as injury biomarker |
| Mechanism | Description |
|---|---|
| Microtubule disruption | Loss of stabilization leads to transport defects |
| Synaptic loss | Reduced synaptic MAP2 precedes neuron death |
| Phosphorylation imbalance | Abnormal kinases/phosphatases affect MAP2 |
| Proteasomal degradation | Increased MAP2 cleavage in disease |
| Biomarker Use | Application | Reliability |
|---|---|---|
| Neuronal injury | CSF/serum MAP2 | Research stage |
| Disease progression | Brain MAP2 loss | Established |
| Therapeutic monitoring | MAP2 recovery | Experimental |
| Autopsy tissue | MAP2 immunostaining | Standard pathology |
| Partner | Interaction Type | Function |
|---|---|---|
| β-Tubulin | Direct binding | Microtubule stabilization |
| Tau | Competition | Microtubule binding |
| PSD-95 | Scaffold binding | Synaptic targeting |
| NMDA receptor | Direct binding | Synaptic signaling |
| CaMKII | Phosphorylation | Activity regulation |
| MARK kinases | Phosphorylation | Microtubule dynamics |
| Fyn kinase | Phosphorylation | Tyrosine modification |
MAP2 participates in several key pathways:
Map2 knockout mice exhibit:
| Region | MAP2 Expression |
|---|---|
| Hippocampus | Very high (CA1-CA3, dentate gyrus) |
| Cerebral cortex | High (layers II-VI) |
| Cerebellum | Moderate (Purkinje cell dendrites) |
| Basal ganglia | Moderate |
| Brainstem | Lower |
| Kinase | Site | Effect |
|---|---|---|
| CaMKII | Multiple serine/threonine | Modulates binding |
| PKA | Serine residues | Reduces binding |
| MARK/PAR-1 | KXGS motifs | Dissociation from MTs |
| GSK-3β | Multiple sites | Disease relevance |
| CDK5 | Proline-directed sites | Development |
Shafit-Zagardo et al. [MAP2 isoforms (1999)](https://doi.org/10.1016/S0165-5728(98). 1999. ↩︎
Johnson et al. [MAP2 and cytoskeletal signaling (2000)](https://doi.org/10.1016/S0092-8674(00). 2000. ↩︎
Baudier et al. MAP2 phosphorylation by kinases (1987). 1987. ↩︎
Tucker et al. MAP2 in dendritic spines (1990). 1990. ↩︎
Avila et al. [Tau and MAP2 in disease (1994)](https://doi.org/10.1016/0301-0082(94). 1994. ↩︎
Mandelkow et al. [MAP2 interactions with tau (1995)](https://doi.org/10.1016/0166-2236(95). 1995. ↩︎
Squier et al. [MAP2 in developmental neurobiology (2001)](https://doi.org/10.1016/S0301-0082(00). 2001. ↩︎
Fischer et al. MAP2 and cognitive decline (2009). 2009. ↩︎
Merriam et al. MAP2 gene regulation (1983). 1983. ↩︎
Drubin et al. MAP2 and neuronal polarity (1985). 1985. ↩︎